uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results

uniQure (NASDAQ:QURE) released its quarterly earnings data on Wednesday. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40), FiscalAI reports. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. During the same period last year, the company earned ($0.69) earnings per share.

Here are the key takeaways from uniQure’s conference call:

• AMT-130 remains on track for a U.S. BLA submission in the third quarter under the FDA’s Accelerated Approval pathway, with three-year Phase I/II data accepted as the primary basis. A U.K. submission to the MHRA is also planned for the third quarter.
• The FDA indicated that a confirmatory study may use a randomized standard-of-care control rather than a sham procedure, potentially simplifying execution. uniQure expects to align on the design and begin a global study promptly, with Total Functional Capacity at 36 months under consideration as the primary endpoint.
• uniQure expects to present four-year AMT-130 data in September, including safety, tolerability, functional outcomes, natural-history comparisons and CSF neurofilament light data. Management is in a quiet period and declined to provide additional commentary on the results ahead of the readout.
• Early AMT-260 epilepsy data showed seizure reductions of 79% to 100% below baseline in three of six low-dose patients, but outcomes varied widely among the remaining participants; higher-dose enrollment is nearly complete. AMT-191 produced dose-dependent enzyme activity increases in all 11 patients, although two grade 3 liver-enzyme events paused further mid- and high-dose dosing pending FDA agreement on monitoring.
• Cash, cash equivalents and investments totaled $810.3 million at quarter-end, up from $622.5 million at year-end 2025, and management expects the balance sheet to fund operations, the confirmatory trial, potential AMT-130 launches and ongoing development into 2030.

uniQure Price Performance

QURE traded up $1.24 during trading on Friday, hitting $43.42. The company’s stock had a trading volume of 1,023,282 shares, compared to its average volume of 2,569,125. The company has a current ratio of 10.01, a quick ratio of 10.40 and a debt-to-equity ratio of 0.15. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50. The business’s fifty day simple moving average is $37.10 and its 200 day simple moving average is $26.13. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of -10.83 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Several research firms have commented on QURE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Chardan Capital raised their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. The Goldman Sachs Group lifted their price target on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, June 18th. Mizuho upped their price objective on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

Insider Buying and Selling at uniQure

In related news, insider Kylie O’keefe sold 15,936 shares of uniQure stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This trade represents a 12.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 433,229 shares of company stock worth $17,944,799. 4.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. State Street Corp increased its stake in shares of uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. MPM Bioimpact LLC purchased a new position in uniQure in the 4th quarter valued at about $33,062,000. Suvretta Capital Management LLC acquired a new stake in uniQure in the 4th quarter worth about $29,116,000. Finally, Sofinnova Investments Inc. boosted its holdings in uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.